-
Mashup Score: 0Corticosteroid Responsiveness Following Mepolizumab in Severe Eosinophilic Asthma—A Randomized, Placebo-Controlled Crossover Trial (MAPLE) - 2 year(s) ago
Mepolizumab inhibits IL-5 activity and reduces exacerbation frequency and maintenance oral corticosteroid (OCS) dosage in patients with severe eosinophilic asthma (SEA). Some patients remain dependent on OCS despite anti–IL-5 treatment, suggesting residual corticosteroid-responsive mechanisms.
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 3REALITI-A Study: Real-World Oral Corticosteroid-Sparing Effect of Mepolizumab in Severe Asthma - 2 year(s) ago
Patients with severe asthma may require maintenance oral corticosteroids (mOCS) for disease control as well as systemic corticosteroid (SCS) bursts for clinically significant exacerbations. However, mOCS and SCS use are associated with adverse effects, which increases patient disease burden.
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0
Hypereosinophilic syndromes (HES) are a heterogeneous group of disorders characterized by a massive persistent expansion of eosinophils and signs of eosinophil-induced organ damage.1-5 Hypereosinophilic syndromes can be divided into primary HES, in which eosinophils are clonal cells and a myeloid or stem cell neoplasm is usually diagnosed; secondary (reactive) HES, in which an underlying reactive…
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 1Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5 - 2 year(s) ago
Mepolizumab, an anti-interleukin-5 (IL-5) antibody, reduces disease flares in patients with hypereosinophilic syndrome (HES). Factors predicting treatment response are unknown.
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 6Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study - 2 year(s) ago
Eosinophilic granulomatosis with polyangiitis (EGPA) is an anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis characterised by eosinophilic (eg, respiratory involvement, cardiomyopathy, gastroenteritis) and vasculitic manifestations (eg, neuropathy, glomerulonephritis).1 Rituximab is an established treatment in granulomatosis with polyangiitis and microscopic polyangiitis, and…
Source: Annals of the Rheumatic DiseasesCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 1Impact of mepolizumab in patients with high-burden severe asthma within a managed care population - PubMed - 2 year(s) ago
Objective: To evaluate the real-world impact of mepolizumab on the incidence of asthma exacerbations, oral corticosteroid (OCS) use and asthma exacerbation-related costs in patients with high-burden severe asthma.Methods: This was a retrospective study of the MarketScan Commerci …
Source: PubMedCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 3Corticosteroid responsiveness following mepolizumab in severe eosinophilic asthma - a randomised, placebo-controlled crossover trial [MAPLE] - 2 year(s) ago
Mepolizumab inhibits interleukin-5 (IL-5) activity, reduces exacerbation frequency and maintenance oral corticosteroid (OCS) dosage in patients with severe eosinophilic asthma (SEA). Some patients remain dependent on OCS despite anti-IL-5 treatment suggesting residual corticosteroid responsive mechanisms.
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 2
Eosinophilic bronchiolitis (EB) is a rare disease characterized in adults by (1) blood hypereosinophilia greater than 1 g·L−1 and/or bronchoalveolar lavage (BAL) eosinophilia greater than 25%, (2) airflow obstruction not improved by inhaled bronchodilators and corticosteroids, and (3) direct signs of bronchiolitis on imaging or lung biopsy.1,2 Individuals with EB present with severe persistent…
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 6Safety and Efficacy of Mepolizumab in Hypereosinophilic Syndrome: An Open-Label Extension Study - 2 year(s) ago
A double-blind, placebo-controlled, phase III study (200622) showed that mepolizumab reduces disease flares for patients with uncontrolled FIP1-like-1-platelet-derived growth factor receptor α–negative hypereosinophilic syndrome (HES) and two or more flares in the previous year.
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0
Article InfoPublication HistoryAccepted: October 27, 2021Received in revised form: October 14, 2021Received: July 23, 2021Publication stageIn Press Journal Pre-ProofFootnotesDisclosures: The Authors have no disclosures.Clinical Implications: This is the first reported case of a pediatric patient with biopsy-confirmed…
Categories: Allergy-Immunology, Latest HeadlinesTweet
In Current Issue! #Corticosteroid #Responsiveness Following #Mepolizumab in #Severe #Eosinophilic #Asthma—A Randomized, Placebo-Controlled Crossover Trial ( #MAPLE) https://t.co/zvzVTrybPx https://t.co/UmrUJZmZPF